Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance [Phase 2, Phase 3]

View source ↗

Summary

The document reports a Phase 2/3 study evaluating lenacapavir (GS-6207) in combination with an optimized background regimen for heavily treatment-experienced pe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lenacapavir (lenacapavir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-infection | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-10-20